Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
about
Conditioning regimens for hematopoietic cell transplantation: one size does not fit allHematopoietic stem cell transplantation-50 years of evolution and future perspectives.Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.The G⁵¹⁶T CYP2B6 germline polymorphism affects the risk of acute myeloid leukemia and is associated with specific chromosomal abnormalitiesLate toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children.Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of thEfficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation.Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy.A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array TestingTherapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial.Kinetics of versican-expressing macrophages in bone marrow after cord blood stem cell transplantation for treatment of acute myelogenous leukaemia.Gli-1/PI3K/AKT/NF-kB pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.Aldehyde dehydrogenases in acute myeloid leukemia.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.Complications of allogeneic hematopoietic stem cell transplantation.Conditioning regimens in acute myeloid leukemia.Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT.Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity.Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics.Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy.Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis.Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation.Against the odds: haplo-cord grafts protect from GvHD and relapse.Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
P2860
Q33917170-45C87EDC-CC1E-4718-A5A0-8AE9E8DFEC8BQ34463419-74D43073-1007-4601-A907-A917EBA270FFQ35085078-A1E926D4-4840-43C1-A906-B044652EBCC8Q35106387-3731B0E4-3B20-4C8D-9F1F-1259367425A3Q35110623-1597D3A9-74D4-440F-AA98-6EFA5C2833BBQ35586590-3DE100CC-B342-4873-955D-56EC47A1418EQ35859239-5863EEDF-0873-4B12-ACC3-A22B5653E893Q36019981-BEC80A17-0695-4D09-B41F-3D5F92F96D77Q36025319-AEA36C49-C7F5-45A2-8D1B-25B4905E4ACDQ36157163-F0FF5AEA-C3DB-49C0-8BCD-23732E8C1329Q36220882-4CCB8186-3487-4E9A-9E11-5C096C6A3AA8Q36264692-9CBBB181-CABF-4657-BE31-F3C92D3FB537Q36635154-9E30FE31-AE8F-4369-A294-2A817820C583Q36703516-5A0B2D42-14C8-4A8A-81C4-EEA794BA30DCQ36715911-A8813228-078C-4011-A77A-26D049E431FAQ37310229-CB350FE3-0A03-4D23-94C7-0A94BBBF780EQ37362827-8D6FCCC0-8B58-4CB8-9C6B-FF131B243727Q37624593-08212D88-9F4C-4432-901E-FE2D08740C3FQ37738997-0BE86B9E-5A06-4F5D-A790-C9F59C9D5BA5Q38196948-1E1233B2-1412-4309-A1A2-71E841BC0C6DQ38199056-1026A07D-E71B-4E42-B293-7195F5B38439Q38207595-BD8CCF0D-F3BD-4CD2-89DE-4B1845BFB749Q38217938-1625BFEA-43AC-420B-99F7-BA64D71FFC32Q38229633-11EC160C-E4BF-4472-B9D6-97046AF3C72CQ38248427-01EB1207-001B-428C-B148-8522F4A15DF8Q38777460-88C4642D-10F7-45AB-8A68-3E72FBF3F02EQ38847841-8F526A20-7807-4282-81E5-D5C7C534EF5CQ39632454-116EE77A-C809-4A2A-BC12-36A6A2619921Q40121414-E27DE517-FDF1-4B4E-B8DD-974324D42C2FQ40262357-EE1C3AFF-3EB5-4C2D-8557-D874075D677BQ40280061-727EFECE-5DAE-4705-A589-3B761B4EAC59Q40815983-B9F7FF64-886B-4DFC-B8EC-209D6DB5417EQ41039242-361D3600-DF45-4847-9942-D48DA4C9D96FQ41200444-1EA9D7F6-03FA-4B33-B649-C5E2228012D4Q41653330-075E3386-C98A-4E2C-A545-25B45CC39B9BQ50260074-E8E09B72-741F-4D4F-99D0-1356F1285B79Q50887405-D6BF19AD-FF94-4955-BF59-31A6E9EC5BE5Q50924228-C12511A3-DC00-48E5-8A09-36A5A4237578Q53211922-7AA0F919-5116-49F0-8C12-F79D900149ABQ55037985-4EAE1EB6-1474-4E40-A89E-BFEBBDAD02DE
P2860
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Better leukemia-free and overa ...... th busulfan compared with TBI.
@en
Better leukemia-free and overa ...... th busulfan compared with TBI.
@nl
type
label
Better leukemia-free and overa ...... th busulfan compared with TBI.
@en
Better leukemia-free and overa ...... th busulfan compared with TBI.
@nl
prefLabel
Better leukemia-free and overa ...... th busulfan compared with TBI.
@en
Better leukemia-free and overa ...... th busulfan compared with TBI.
@nl
P2093
P2860
P1433
P1476
Better leukemia-free and overa ...... th busulfan compared with TBI.
@en
P2093
Alison W Loren
Baldeep Wirk
Belinda Avalos
Betty K Hamilton
Bipin N Savani
Brian J Bolwell
Celalettin Ustun
Christopher Bredeson
Daniel J Weisdorf
David I Marks
P2860
P304
P356
10.1182/BLOOD-2013-07-514448
P407
P577
2013-09-24T00:00:00Z